Rare Disease

Aaron Farberg, MD, presents study data and efficacy of spesolimab for the treatment of generalized pustular psoriasis at the 2022 Fall Clinical Dermatology Conference.

At the 2022 Fall Clinical Dermatology Conference, a look at the latest treatments for monkeypox, HIV, and more.

How to diagnose and treat this rare skin disorder.

Patients with generalized pustular psoriasis flares were 2 times more likely to have emergency department visits.

Thorough history taking is essential during the consultation and can help clinicians rule out other potential differential diagnoses.

Click here to answer this week's poll.

Bristol Myers Squibb’s nivolumab shows potential for treatment in earlier stages of melanoma.

TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.

At the 2022 National Infusion Center Association Annual Conference, Kelly Gordon, PharmD, answered why diagnosing GPP is so difficult and what to look for to optimize patient care.

Timber Pharmaceuticals has received an FDA breakthrough therapy designation for TMB-001 for the treatment of congenital ichthyosis.

The 3rd Annual San Diego Dermatology Symposium (SDDS) was held in-person for the first time on March 11 to 13, 2022, at the Hilton San Diego Bayfront, in California.

New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.